07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Nicox, Rapid Pathogen Screening deal

Nicox said it has paid a total of $3 million to RPS in license and option fees and has contributed to half of the development costs of RPS-AP and RPS-OH. Under the amended agreement, Nicox...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Nicox, Rapid Pathogen Screening deal

Rapid granted NicOx exclusive, worldwide rights to commercialize several ophthalmic diagnostics.The deal includes AdenoPlus adenoviral conjunctivitis diagnostic and two diagnostics in development - RPS-AP for detecting adenoviral and allergic conjunctivitis and RPS-OH to diagnose ocular...